AVTX
NASDAQAvalo Therapeutics Inc.
News · 26 weeks85+7%
2025-12-072026-05-31
Mix5690d
- Insider26(46%)
- SEC Filings14(25%)
- Other11(20%)
- Offering3(5%)
- Analyst2(4%)
Latest news
25 items- INSIDERChief Medical Officer Doyle Mittie exercised 679 shares at a strike of $8.04 and sold $10,864 worth of shares (679 units at $16.00) as part of a pre-agreed trading plan (SEC Form 4)4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
- INSIDERChief Executive Officer Neil Garry Arthur was granted 100,200 shares, increasing direct ownership by 111% to 190,314 units (SEC Form 4)4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
- INSIDERChief Legal Officer Varki Paul was granted 24,300 shares, increasing direct ownership by 669% to 27,934 units (SEC Form 4)4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
- INSIDERChief Medical Officer Doyle Mittie was granted 43,500 shares, increasing direct ownership by 1,201% to 47,122 units (SEC Form 4)4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
- INSIDERChief Financial Officer Sullivan Christopher Ryan was granted 39,900 shares, increasing direct ownership by 9,433% to 40,323 units (SEC Form 4)4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
- INSIDERChief Strategy Officer Riley Jennifer was granted 34,200 shares, increasing direct ownership by 1,288% to 36,855 units (SEC Form 4)4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
- PRAvalo Therapeutics Announces Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)WAYNE, PA., May 22, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced that the Company granted an inducement award consisting of an option to purchase 34,000 shares of its common stock to one new employee (the "Option"). The award was approved by the Compensation Committee of the Board of Directors as an inducement material to the employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The Option was granted on May 21, 2026 and has an exercise price of $16.60 per share, which is e
- INSIDERChief Medical Officer Doyle Mittie sold $56,280 worth of shares (3,000 units at $18.76) as part of a pre-agreed trading plan and exercised 3,000 shares at a strike of $12.65 (SEC Form 4)4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Avalo Therapeutics Inc.SCHEDULE 13G/A - Avalo Therapeutics, Inc. (0001534120) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Avalo Therapeutics Inc.SCHEDULE 13G/A - Avalo Therapeutics, Inc. (0001534120) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Avalo Therapeutics Inc.SCHEDULE 13G/A - Avalo Therapeutics, Inc. (0001534120) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Avalo Therapeutics Inc.SCHEDULE 13G/A - Avalo Therapeutics, Inc. (0001534120) (Subject)
- SECSEC Form 10-Q filed by Avalo Therapeutics Inc.10-Q - Avalo Therapeutics, Inc. (0001534120) (Filer)
- SECAvalo Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Avalo Therapeutics, Inc. (0001534120) (Filer)
- PRAvalo Therapeutics Reports First Quarter 2026 Financial Results and Recent Business UpdatesAchieved positive topline results in Phase 2 LOTUS trial of abdakibart in moderate to severe hidradenitis suppurativa (HS) and plan to advance into a registrational phase 3 programCompleted public offering of equity securities for gross proceeds of $431.3 million Cash, cash equivalents, and short-term investments of $82 million as of March 31, 2026, not including the subsequent financing WAYNE, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX) ("Avalo"), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced business updates and first quarter 2026 financial results.
- INSIDERChief Financial Officer Sullivan Christopher Ryan sold $448,818 worth of shares (18,606 units at $24.12) as part of a pre-agreed trading plan and exercised 18,606 shares at a strike of $9.88 (SEC Form 4)4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
- INSIDERChief Legal Officer Varki Paul exercised 75,063 shares at a strike of $12.53 and sold $1,513,673 worth of shares (75,063 units at $20.17) as part of a pre-agreed trading plan (SEC Form 4)4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
- INSIDERChief Medical Officer Doyle Mittie exercised 108,234 shares at a strike of $11.40 and sold $2,230,367 worth of shares (108,234 units at $20.61) as part of a pre-agreed trading plan (SEC Form 4)4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
- INSIDERChief Financial Officer Sullivan Christopher Ryan exercised 47,000 shares at a strike of $8.04 and sold $948,722 worth of shares (47,000 units at $20.19) as part of a pre-agreed trading plan (SEC Form 4)4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
- INSIDERDirector Chan Mitchell sold $72,461 worth of shares (3,167 units at $22.88) as part of a pre-agreed trading plan, decreasing direct ownership by 50% to 3,166 units (SEC Form 4)4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
- SECSEC Form 424B5 filed by Avalo Therapeutics Inc.424B5 - Avalo Therapeutics, Inc. (0001534120) (Filer)
- SECAvalo Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Avalo Therapeutics, Inc. (0001534120) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Avalo Therapeutics Inc.SCHEDULE 13G/A - Avalo Therapeutics, Inc. (0001534120) (Subject)
- PRAvalo Therapeutics Announces Pricing of $375 Million Public OfferingWAYNE, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX) ("Avalo"), a clinical-stage biotechnology company fully dedicated to developing IL-1β based treatments for immune-mediated inflammatory diseases, today announced the pricing of its underwritten public offering of 19,730,000 shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,400,000 shares of common stock. The shares of common stock are being sold at a public offering price of $17.75 per share and the pre-funded warrants are being sold at a public offering price of $17.749 per pre-funded warrant, which represents the per share public offering price of
- SECSEC Form 424B5 filed by Avalo Therapeutics Inc.424B5 - Avalo Therapeutics, Inc. (0001534120) (Filer)
AVTX FAQ
6 questionsWhere does AVTX stock trade?
Avalo Therapeutics Inc. (AVTX) is listed on NASDAQ.What sector and industry is AVTX in?
Avalo Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Avalo Therapeutics Inc. go public?
Avalo Therapeutics Inc. (AVTX) completed its IPO in 2015.What are analysts saying about AVTX?
Avalo Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Wolfe Research: Outperform with a $4800.00 price target on 2026-04-09. Recent price targets range from $1500.00 to $4800.00.What companies are similar to AVTX?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare AVTX side-by-side with any of them on Quantisnow.How can I track AVTX on Quantisnow?
Quantisnow aggregates Avalo Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AVTX to receive live email and push alerts on every new disclosure.